Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06428045 · ClinicalTrials.gov registry record · Phase 1
STARLITE for Unresectable High-Grade Gliomas
A Phase 1 study of High Grade Glioma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06428045 is a Phase 1 study of High Grade Glioma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 24 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06428045, a Phase 1 study of High Grade Glioma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.
Conditions Studied
Interventions
- DRUG Temozolomide
- PROCEDURE Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)
- DRUG Abacavir
- DRUG Lamivudine
- DRUG Ritonavir
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06428045
The ClinicalTrials.gov registry entry for NCT06428045 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (63% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT06428045 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06428045 about?
NCT06428045 is a clinical study titled "STARLITE for Unresectable High-Grade Gliomas". The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grad...
What is the current status of trial NCT06428045?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-04-15. Estimated completion is 2030-04-30.
What conditions does trial NCT06428045 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT06428045?
The interventions under investigation include: Temozolomide (DRUG), Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT) (PROCEDURE), Abacavir (DRUG), Lamivudine (DRUG), Ritonavir (DRUG).
Who is sponsoring clinical trial NCT06428045?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06428045 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.